nodes	percent_of_prediction	percent_of_DWPC	metapath
Orlistat—PNLIP—exocrine gland—head and neck cancer	0.03	0.0914	CbGeAlD
Orlistat—PNLIP—mouth—head and neck cancer	0.0224	0.0683	CbGeAlD
Orlistat—ABHD16A—parotid gland—head and neck cancer	0.0167	0.0508	CbGeAlD
Orlistat—ABHD16A—saliva-secreting gland—head and neck cancer	0.016	0.0486	CbGeAlD
Orlistat—PLA2G7—connective tissue—head and neck cancer	0.0156	0.0476	CbGeAlD
Orlistat—ABHD12—parotid gland—head and neck cancer	0.0156	0.0476	CbGeAlD
Orlistat—ABHD12—saliva-secreting gland—head and neck cancer	0.015	0.0456	CbGeAlD
Orlistat—DAGLA—head—head and neck cancer	0.0147	0.0448	CbGeAlD
Orlistat—PNLIP—connective tissue—head and neck cancer	0.0137	0.0419	CbGeAlD
Orlistat—DAGLB—thyroid gland—head and neck cancer	0.0129	0.0392	CbGeAlD
Orlistat—FASN—saliva-secreting gland—head and neck cancer	0.0126	0.0382	CbGeAlD
Orlistat—ABHD16A—trachea—head and neck cancer	0.0123	0.0375	CbGeAlD
Orlistat—ABHD12—trachea—head and neck cancer	0.0115	0.0352	CbGeAlD
Orlistat—PLA2G7—lymphoid tissue—head and neck cancer	0.0114	0.0348	CbGeAlD
Orlistat—PLA2G7—thyroid gland—head and neck cancer	0.0104	0.0316	CbGeAlD
Orlistat—ABHD16A—thyroid gland—head and neck cancer	0.00975	0.0297	CbGeAlD
Orlistat—FASN—trachea—head and neck cancer	0.00969	0.0295	CbGeAlD
Orlistat—ABHD12—thyroid gland—head and neck cancer	0.00913	0.0278	CbGeAlD
Orlistat—Gastrointestinal symptom NOS—Hydroxyurea—head and neck cancer	0.00883	0.0255	CcSEcCtD
Orlistat—PNLIP—head—head and neck cancer	0.0081	0.0247	CbGeAlD
Orlistat—Reaction gastrointestinal—Docetaxel—head and neck cancer	0.00808	0.0234	CcSEcCtD
Orlistat—DAGLB—lymph node—head and neck cancer	0.00799	0.0243	CbGeAlD
Orlistat—Lower respiratory tract infection—Docetaxel—head and neck cancer	0.0079	0.0228	CcSEcCtD
Orlistat—Enteritis—Docetaxel—head and neck cancer	0.0079	0.0228	CcSEcCtD
Orlistat—FASN—thyroid gland—head and neck cancer	0.00766	0.0233	CbGeAlD
Orlistat—Bullous eruption—Docetaxel—head and neck cancer	0.00683	0.0197	CcSEcCtD
Orlistat—PLA2G7—lymph node—head and neck cancer	0.00645	0.0196	CbGeAlD
Orlistat—Gastrointestinal symptom NOS—Fluorouracil—head and neck cancer	0.00636	0.0184	CcSEcCtD
Orlistat—Rectal haemorrhage—Vinblastine—head and neck cancer	0.0063	0.0182	CcSEcCtD
Orlistat—ABHD16A—lymph node—head and neck cancer	0.00605	0.0184	CbGeAlD
Orlistat—PLA2G4A—saliva-secreting gland—head and neck cancer	0.00604	0.0184	CbGeAlD
Orlistat—Amenorrhoea—Hydroxyurea—head and neck cancer	0.00591	0.0171	CcSEcCtD
Orlistat—Nail disorder—Fluorouracil—head and neck cancer	0.00576	0.0167	CcSEcCtD
Orlistat—ABHD12—lymph node—head and neck cancer	0.00567	0.0173	CbGeAlD
Orlistat—PLA2G4A—connective tissue—head and neck cancer	0.00555	0.0169	CbGeAlD
Orlistat—Neoplasm—Vinblastine—head and neck cancer	0.00515	0.0149	CcSEcCtD
Orlistat—Menstruation irregular—Docetaxel—head and neck cancer	0.00487	0.0141	CcSEcCtD
Orlistat—FASN—lymph node—head and neck cancer	0.00476	0.0145	CbGeAlD
Orlistat—Neoplasm—Hydroxyurea—head and neck cancer	0.0047	0.0136	CcSEcCtD
Orlistat—PLA2G4A—trachea—head and neck cancer	0.00466	0.0142	CbGeAlD
Orlistat—Haemorrhoids—Docetaxel—head and neck cancer	0.00459	0.0133	CcSEcCtD
Orlistat—Hepatic failure—Hydroxyurea—head and neck cancer	0.00419	0.0121	CcSEcCtD
Orlistat—Nail disorder—Docetaxel—head and neck cancer	0.00416	0.012	CcSEcCtD
Orlistat—Dermatitis bullous—Hydroxyurea—head and neck cancer	0.00394	0.0114	CcSEcCtD
Orlistat—PLA2G4A—thyroid gland—head and neck cancer	0.00368	0.0112	CbGeAlD
Orlistat—Breast disorder—Hydroxyurea—head and neck cancer	0.00341	0.00985	CcSEcCtD
Orlistat—Pancreatitis—Hydroxyurea—head and neck cancer	0.00319	0.00924	CcSEcCtD
Orlistat—Depression—Vinblastine—head and neck cancer	0.00318	0.00919	CcSEcCtD
Orlistat—Neuropathy peripheral—Vinblastine—head and neck cancer	0.00312	0.00903	CcSEcCtD
Orlistat—Amenorrhoea—Docetaxel—head and neck cancer	0.00307	0.00888	CcSEcCtD
Orlistat—Drug interaction—Docetaxel—head and neck cancer	0.00291	0.00841	CcSEcCtD
Orlistat—Infestation NOS—Hydroxyurea—head and neck cancer	0.00291	0.0084	CcSEcCtD
Orlistat—Infestation—Hydroxyurea—head and neck cancer	0.00291	0.0084	CcSEcCtD
Orlistat—Haemoglobin—Vinblastine—head and neck cancer	0.00287	0.00831	CcSEcCtD
Orlistat—Haemorrhage—Vinblastine—head and neck cancer	0.00286	0.00827	CcSEcCtD
Orlistat—Neuropathy peripheral—Hydroxyurea—head and neck cancer	0.00285	0.00824	CcSEcCtD
Orlistat—Dermatitis bullous—Fluorouracil—head and neck cancer	0.00284	0.00821	CcSEcCtD
Orlistat—Pharyngitis—Vinblastine—head and neck cancer	0.00284	0.00821	CcSEcCtD
Orlistat—Hepatobiliary disease—Hydroxyurea—head and neck cancer	0.00275	0.00795	CcSEcCtD
Orlistat—Osteoarthritis—Fluorouracil—head and neck cancer	0.00271	0.00785	CcSEcCtD
Orlistat—Haemoglobin—Hydroxyurea—head and neck cancer	0.00262	0.00758	CcSEcCtD
Orlistat—Haemorrhage—Hydroxyurea—head and neck cancer	0.00261	0.00754	CcSEcCtD
Orlistat—Alopecia—Vinblastine—head and neck cancer	0.00253	0.00731	CcSEcCtD
Orlistat—Dry skin—Fluorouracil—head and neck cancer	0.00249	0.00719	CcSEcCtD
Orlistat—Neoplasm—Docetaxel—head and neck cancer	0.00244	0.00706	CcSEcCtD
Orlistat—Ill-defined disorder—Vinblastine—head and neck cancer	0.00231	0.00668	CcSEcCtD
Orlistat—Alopecia—Hydroxyurea—head and neck cancer	0.0023	0.00667	CcSEcCtD
Orlistat—PLA2G4A—lymph node—head and neck cancer	0.00229	0.00697	CbGeAlD
Orlistat—Malaise—Vinblastine—head and neck cancer	0.00224	0.00649	CcSEcCtD
Orlistat—Vertigo—Vinblastine—head and neck cancer	0.00224	0.00647	CcSEcCtD
Orlistat—Upper respiratory tract infection—Fluorouracil—head and neck cancer	0.00218	0.0063	CcSEcCtD
Orlistat—Hepatic failure—Docetaxel—head and neck cancer	0.00218	0.0063	CcSEcCtD
Orlistat—Convulsion—Vinblastine—head and neck cancer	0.00216	0.00624	CcSEcCtD
Orlistat—Ill-defined disorder—Hydroxyurea—head and neck cancer	0.00211	0.00609	CcSEcCtD
Orlistat—Discomfort—Vinblastine—head and neck cancer	0.00209	0.00606	CcSEcCtD
Orlistat—Infestation—Fluorouracil—head and neck cancer	0.00209	0.00605	CcSEcCtD
Orlistat—Infestation NOS—Fluorouracil—head and neck cancer	0.00209	0.00605	CcSEcCtD
Orlistat—Menopausal symptoms—Docetaxel—head and neck cancer	0.00208	0.006	CcSEcCtD
Orlistat—Neuropathy peripheral—Fluorouracil—head and neck cancer	0.00205	0.00593	CcSEcCtD
Orlistat—Dermatitis bullous—Docetaxel—head and neck cancer	0.00205	0.00593	CcSEcCtD
Orlistat—Malaise—Hydroxyurea—head and neck cancer	0.00205	0.00592	CcSEcCtD
Orlistat—Urinary tract infection—Fluorouracil—head and neck cancer	0.00203	0.00588	CcSEcCtD
Orlistat—Convulsion—Hydroxyurea—head and neck cancer	0.00197	0.00569	CcSEcCtD
Orlistat—Sinusitis—Fluorouracil—head and neck cancer	0.00196	0.00567	CcSEcCtD
Orlistat—Unspecified disorder of skin and subcutaneous tissue—Hydroxyurea—head and neck cancer	0.00192	0.00555	CcSEcCtD
Orlistat—Discomfort—Hydroxyurea—head and neck cancer	0.00191	0.00552	CcSEcCtD
Orlistat—Haemoglobin—Fluorouracil—head and neck cancer	0.00189	0.00546	CcSEcCtD
Orlistat—Haemorrhage—Fluorouracil—head and neck cancer	0.00188	0.00543	CcSEcCtD
Orlistat—Pharyngitis—Fluorouracil—head and neck cancer	0.00186	0.00539	CcSEcCtD
Orlistat—Oedema—Hydroxyurea—head and neck cancer	0.00185	0.00536	CcSEcCtD
Orlistat—Infection—Hydroxyurea—head and neck cancer	0.00184	0.00532	CcSEcCtD
Orlistat—Paraesthesia—Vinblastine—head and neck cancer	0.00182	0.00528	CcSEcCtD
Orlistat—Nervous system disorder—Hydroxyurea—head and neck cancer	0.00182	0.00526	CcSEcCtD
Orlistat—Skin disorder—Hydroxyurea—head and neck cancer	0.0018	0.00521	CcSEcCtD
Orlistat—Dry skin—Docetaxel—head and neck cancer	0.0018	0.00519	CcSEcCtD
Orlistat—Abdominal pain upper—Docetaxel—head and neck cancer	0.00179	0.00517	CcSEcCtD
Orlistat—Breast disorder—Docetaxel—head and neck cancer	0.00177	0.00512	CcSEcCtD
Orlistat—Decreased appetite—Vinblastine—head and neck cancer	0.00177	0.00511	CcSEcCtD
Orlistat—Cramp muscle—Docetaxel—head and neck cancer	0.00176	0.0051	CcSEcCtD
Orlistat—Pain—Vinblastine—head and neck cancer	0.00174	0.00502	CcSEcCtD
Orlistat—Feeling abnormal—Vinblastine—head and neck cancer	0.00167	0.00484	CcSEcCtD
Orlistat—Bronchospasm—Docetaxel—head and neck cancer	0.00166	0.00482	CcSEcCtD
Orlistat—Gastrointestinal pain—Vinblastine—head and neck cancer	0.00166	0.0048	CcSEcCtD
Orlistat—Alopecia—Fluorouracil—head and neck cancer	0.00166	0.0048	CcSEcCtD
Orlistat—Dyspepsia—Hydroxyurea—head and neck cancer	0.00163	0.00472	CcSEcCtD
Orlistat—Decreased appetite—Hydroxyurea—head and neck cancer	0.00161	0.00466	CcSEcCtD
Orlistat—Abdominal pain—Vinblastine—head and neck cancer	0.00161	0.00465	CcSEcCtD
Orlistat—Gastrointestinal disorder—Hydroxyurea—head and neck cancer	0.0016	0.00463	CcSEcCtD
Orlistat—Fatigue—Hydroxyurea—head and neck cancer	0.0016	0.00462	CcSEcCtD
Orlistat—Pain—Hydroxyurea—head and neck cancer	0.00158	0.00458	CcSEcCtD
Orlistat—Vision blurred—Fluorouracil—head and neck cancer	0.00154	0.00445	CcSEcCtD
Orlistat—Feeling abnormal—Hydroxyurea—head and neck cancer	0.00153	0.00442	CcSEcCtD
Orlistat—Infestation—Docetaxel—head and neck cancer	0.00151	0.00437	CcSEcCtD
Orlistat—Infestation NOS—Docetaxel—head and neck cancer	0.00151	0.00437	CcSEcCtD
Orlistat—Hypersensitivity—Vinblastine—head and neck cancer	0.0015	0.00433	CcSEcCtD
Orlistat—Renal failure—Docetaxel—head and neck cancer	0.00148	0.00429	CcSEcCtD
Orlistat—Neuropathy peripheral—Docetaxel—head and neck cancer	0.00148	0.00428	CcSEcCtD
Orlistat—Body temperature increased—Hydroxyurea—head and neck cancer	0.00146	0.00424	CcSEcCtD
Orlistat—Asthenia—Vinblastine—head and neck cancer	0.00146	0.00422	CcSEcCtD
Orlistat—Hepatobiliary disease—Docetaxel—head and neck cancer	0.00143	0.00413	CcSEcCtD
Orlistat—Convulsion—Fluorouracil—head and neck cancer	0.00142	0.00409	CcSEcCtD
Orlistat—Myalgia—Fluorouracil—head and neck cancer	0.00139	0.00402	CcSEcCtD
Orlistat—Chest pain—Fluorouracil—head and neck cancer	0.00139	0.00402	CcSEcCtD
Orlistat—Diarrhoea—Vinblastine—head and neck cancer	0.00139	0.00402	CcSEcCtD
Orlistat—Discomfort—Fluorouracil—head and neck cancer	0.00137	0.00398	CcSEcCtD
Orlistat—Hypersensitivity—Hydroxyurea—head and neck cancer	0.00137	0.00395	CcSEcCtD
Orlistat—Haemoglobin—Docetaxel—head and neck cancer	0.00136	0.00394	CcSEcCtD
Orlistat—Haemorrhage—Docetaxel—head and neck cancer	0.00135	0.00392	CcSEcCtD
Orlistat—Hepatitis—Docetaxel—head and neck cancer	0.00135	0.00392	CcSEcCtD
Orlistat—Pharyngitis—Docetaxel—head and neck cancer	0.00134	0.00389	CcSEcCtD
Orlistat—Dizziness—Vinblastine—head and neck cancer	0.00134	0.00389	CcSEcCtD
Orlistat—Urinary tract disorder—Docetaxel—head and neck cancer	0.00134	0.00387	CcSEcCtD
Orlistat—Oedema peripheral—Docetaxel—head and neck cancer	0.00133	0.00386	CcSEcCtD
Orlistat—Anaphylactic shock—Fluorouracil—head and neck cancer	0.00133	0.00386	CcSEcCtD
Orlistat—Oedema—Fluorouracil—head and neck cancer	0.00133	0.00386	CcSEcCtD
Orlistat—Asthenia—Hydroxyurea—head and neck cancer	0.00133	0.00384	CcSEcCtD
Orlistat—Urethral disorder—Docetaxel—head and neck cancer	0.00133	0.00384	CcSEcCtD
Orlistat—Infection—Fluorouracil—head and neck cancer	0.00132	0.00383	CcSEcCtD
Orlistat—Nervous system disorder—Fluorouracil—head and neck cancer	0.00131	0.00378	CcSEcCtD
Orlistat—Vomiting—Vinblastine—head and neck cancer	0.00129	0.00374	CcSEcCtD
Orlistat—Headache—Vinblastine—head and neck cancer	0.00127	0.00368	CcSEcCtD
Orlistat—Diarrhoea—Hydroxyurea—head and neck cancer	0.00127	0.00367	CcSEcCtD
Orlistat—Dizziness—Hydroxyurea—head and neck cancer	0.00123	0.00354	CcSEcCtD
Orlistat—Immune system disorder—Docetaxel—head and neck cancer	0.00122	0.00354	CcSEcCtD
Orlistat—Mediastinal disorder—Docetaxel—head and neck cancer	0.00122	0.00353	CcSEcCtD
Orlistat—Musculoskeletal discomfort—Fluorouracil—head and neck cancer	0.00122	0.00351	CcSEcCtD
Orlistat—Nausea—Vinblastine—head and neck cancer	0.00121	0.00349	CcSEcCtD
Orlistat—Insomnia—Fluorouracil—head and neck cancer	0.00121	0.00349	CcSEcCtD
Orlistat—Paraesthesia—Fluorouracil—head and neck cancer	0.0012	0.00346	CcSEcCtD
Orlistat—Alopecia—Docetaxel—head and neck cancer	0.0012	0.00346	CcSEcCtD
Orlistat—Mental disorder—Docetaxel—head and neck cancer	0.00119	0.00343	CcSEcCtD
Orlistat—Malnutrition—Docetaxel—head and neck cancer	0.00118	0.00341	CcSEcCtD
Orlistat—Vomiting—Hydroxyurea—head and neck cancer	0.00118	0.00341	CcSEcCtD
Orlistat—Dyspepsia—Fluorouracil—head and neck cancer	0.00117	0.0034	CcSEcCtD
Orlistat—Rash—Hydroxyurea—head and neck cancer	0.00117	0.00338	CcSEcCtD
Orlistat—Dermatitis—Hydroxyurea—head and neck cancer	0.00117	0.00338	CcSEcCtD
Orlistat—Headache—Hydroxyurea—head and neck cancer	0.00116	0.00336	CcSEcCtD
Orlistat—Decreased appetite—Fluorouracil—head and neck cancer	0.00116	0.00335	CcSEcCtD
Orlistat—Dysgeusia—Docetaxel—head and neck cancer	0.00115	0.00334	CcSEcCtD
Orlistat—Gastrointestinal disorder—Fluorouracil—head and neck cancer	0.00115	0.00333	CcSEcCtD
Orlistat—Back pain—Docetaxel—head and neck cancer	0.00114	0.0033	CcSEcCtD
Orlistat—Pain—Fluorouracil—head and neck cancer	0.00114	0.0033	CcSEcCtD
Orlistat—Muscle spasms—Docetaxel—head and neck cancer	0.00113	0.00328	CcSEcCtD
Orlistat—Nausea—Hydroxyurea—head and neck cancer	0.0011	0.00318	CcSEcCtD
Orlistat—Feeling abnormal—Fluorouracil—head and neck cancer	0.0011	0.00318	CcSEcCtD
Orlistat—Urticaria—Fluorouracil—head and neck cancer	0.00106	0.00306	CcSEcCtD
Orlistat—Body temperature increased—Fluorouracil—head and neck cancer	0.00105	0.00305	CcSEcCtD
Orlistat—Palpitations—Docetaxel—head and neck cancer	0.00104	0.00301	CcSEcCtD
Orlistat—Cough—Docetaxel—head and neck cancer	0.00103	0.00298	CcSEcCtD
Orlistat—Convulsion—Docetaxel—head and neck cancer	0.00102	0.00296	CcSEcCtD
Orlistat—Chest pain—Docetaxel—head and neck cancer	0.001	0.0029	CcSEcCtD
Orlistat—Myalgia—Docetaxel—head and neck cancer	0.001	0.0029	CcSEcCtD
Orlistat—Unspecified disorder of skin and subcutaneous tissue—Docetaxel—head and neck cancer	0.000997	0.00288	CcSEcCtD
Orlistat—Hypersensitivity—Fluorouracil—head and neck cancer	0.000983	0.00284	CcSEcCtD
Orlistat—Dry mouth—Docetaxel—head and neck cancer	0.000982	0.00284	CcSEcCtD
Orlistat—Oedema—Docetaxel—head and neck cancer	0.000963	0.00278	CcSEcCtD
Orlistat—Anaphylactic shock—Docetaxel—head and neck cancer	0.000963	0.00278	CcSEcCtD
Orlistat—Infection—Docetaxel—head and neck cancer	0.000956	0.00277	CcSEcCtD
Orlistat—Nervous system disorder—Docetaxel—head and neck cancer	0.000944	0.00273	CcSEcCtD
Orlistat—Pruritus—Fluorouracil—head and neck cancer	0.000944	0.00273	CcSEcCtD
Orlistat—DAGLB—Gastrin-CREB signalling pathway via PKC and MAPK—HRAS—head and neck cancer	0.000938	0.00288	CbGpPWpGaD
Orlistat—DAGLA—Gastrin-CREB signalling pathway via PKC and MAPK—HRAS—head and neck cancer	0.000938	0.00288	CbGpPWpGaD
Orlistat—Skin disorder—Docetaxel—head and neck cancer	0.000935	0.0027	CcSEcCtD
Orlistat—PLA2G4A—PDGF Pathway—HRAS—head and neck cancer	0.000925	0.00284	CbGpPWpGaD
Orlistat—Diarrhoea—Fluorouracil—head and neck cancer	0.000912	0.00264	CcSEcCtD
Orlistat—Dizziness—Fluorouracil—head and neck cancer	0.000882	0.00255	CcSEcCtD
Orlistat—PNLIP—Metabolism—DPYD—head and neck cancer	0.000879	0.0027	CbGpPWpGaD
Orlistat—Musculoskeletal discomfort—Docetaxel—head and neck cancer	0.000877	0.00254	CcSEcCtD
Orlistat—Insomnia—Docetaxel—head and neck cancer	0.000871	0.00252	CcSEcCtD
Orlistat—Paraesthesia—Docetaxel—head and neck cancer	0.000864	0.0025	CcSEcCtD
Orlistat—Vomiting—Fluorouracil—head and neck cancer	0.000848	0.00245	CcSEcCtD
Orlistat—Dyspepsia—Docetaxel—head and neck cancer	0.000847	0.00245	CcSEcCtD
Orlistat—PLA2G4A—Fc-epsilon receptor I signaling in mast cells—MAPK3—head and neck cancer	0.000847	0.0026	CbGpPWpGaD
Orlistat—DAGLB—Signaling Pathways—YAP1—head and neck cancer	0.000842	0.00258	CbGpPWpGaD
Orlistat—DAGLA—Signaling Pathways—YAP1—head and neck cancer	0.000842	0.00258	CbGpPWpGaD
Orlistat—Rash—Fluorouracil—head and neck cancer	0.000841	0.00243	CcSEcCtD
Orlistat—Dermatitis—Fluorouracil—head and neck cancer	0.00084	0.00243	CcSEcCtD
Orlistat—Decreased appetite—Docetaxel—head and neck cancer	0.000837	0.00242	CcSEcCtD
Orlistat—Headache—Fluorouracil—head and neck cancer	0.000835	0.00242	CcSEcCtD
Orlistat—PNLIP—Metabolism—YAP1—head and neck cancer	0.000834	0.00256	CbGpPWpGaD
Orlistat—PLA2G4A—AGE/RAGE pathway—STAT3—head and neck cancer	0.000832	0.00255	CbGpPWpGaD
Orlistat—Gastrointestinal disorder—Docetaxel—head and neck cancer	0.000831	0.0024	CcSEcCtD
Orlistat—Fatigue—Docetaxel—head and neck cancer	0.00083	0.0024	CcSEcCtD
Orlistat—PLA2G4A—Endothelins—MAPK3—head and neck cancer	0.000825	0.00253	CbGpPWpGaD
Orlistat—Pain—Docetaxel—head and neck cancer	0.000823	0.00238	CcSEcCtD
Orlistat—PLA2G4A—Integrated Pancreatic Cancer Pathway—TYMS—head and neck cancer	0.000818	0.00251	CbGpPWpGaD
Orlistat—PNLIP—Signaling Pathways—GRP—head and neck cancer	0.000812	0.00249	CbGpPWpGaD
Orlistat—DAGLA—Platelet activation, signaling and aggregation—AKT1—head and neck cancer	0.00081	0.00249	CbGpPWpGaD
Orlistat—DAGLB—Platelet activation, signaling and aggregation—AKT1—head and neck cancer	0.00081	0.00249	CbGpPWpGaD
Orlistat—PLA2G4A—Fc-epsilon receptor I signaling in mast cells—MAPK1—head and neck cancer	0.000806	0.00247	CbGpPWpGaD
Orlistat—PLA2G4A—AGE/RAGE pathway—MAPK3—head and neck cancer	0.000795	0.00244	CbGpPWpGaD
Orlistat—Feeling abnormal—Docetaxel—head and neck cancer	0.000793	0.00229	CcSEcCtD
Orlistat—Nausea—Fluorouracil—head and neck cancer	0.000792	0.00229	CcSEcCtD
Orlistat—PNLIP—Signaling Pathways—STAT6—head and neck cancer	0.000788	0.00242	CbGpPWpGaD
Orlistat—Gastrointestinal pain—Docetaxel—head and neck cancer	0.000787	0.00228	CcSEcCtD
Orlistat—PLA2G4A—Endothelins—MAPK1—head and neck cancer	0.000785	0.00241	CbGpPWpGaD
Orlistat—DAGLA—Hemostasis—IL2—head and neck cancer	0.00077	0.00236	CbGpPWpGaD
Orlistat—DAGLB—Hemostasis—IL2—head and neck cancer	0.00077	0.00236	CbGpPWpGaD
Orlistat—Body temperature increased—Docetaxel—head and neck cancer	0.000761	0.0022	CcSEcCtD
Orlistat—Abdominal pain—Docetaxel—head and neck cancer	0.000761	0.0022	CcSEcCtD
Orlistat—PLA2G4A—AGE/RAGE pathway—MAPK1—head and neck cancer	0.000756	0.00232	CbGpPWpGaD
Orlistat—PLA2G4A—AGE/RAGE pathway—EGFR—head and neck cancer	0.000756	0.00232	CbGpPWpGaD
Orlistat—FASN—Metabolism of lipids and lipoproteins—GPX1—head and neck cancer	0.000754	0.00231	CbGpPWpGaD
Orlistat—FASN—Metabolism of lipids and lipoproteins—CYP1A1—head and neck cancer	0.000746	0.00229	CbGpPWpGaD
Orlistat—PLA2G4A—Metabolism—UROD—head and neck cancer	0.000733	0.00225	CbGpPWpGaD
Orlistat—FASN—Metabolism—NAT2—head and neck cancer	0.00071	0.00218	CbGpPWpGaD
Orlistat—Hypersensitivity—Docetaxel—head and neck cancer	0.000709	0.00205	CcSEcCtD
Orlistat—PLA2G4A—Fc-epsilon receptor I signaling in mast cells—PIK3CA—head and neck cancer	0.000699	0.00214	CbGpPWpGaD
Orlistat—PNLIP—Signaling Pathways—YAP1—head and neck cancer	0.000698	0.00214	CbGpPWpGaD
Orlistat—Asthenia—Docetaxel—head and neck cancer	0.000691	0.002	CcSEcCtD
Orlistat—Pruritus—Docetaxel—head and neck cancer	0.000681	0.00197	CcSEcCtD
Orlistat—Diarrhoea—Docetaxel—head and neck cancer	0.000659	0.0019	CcSEcCtD
Orlistat—DAGLB—Hemostasis—VEGFA—head and neck cancer	0.000655	0.00201	CbGpPWpGaD
Orlistat—DAGLA—Hemostasis—VEGFA—head and neck cancer	0.000655	0.00201	CbGpPWpGaD
Orlistat—PLA2G4A—Fc-epsilon receptor I signaling in mast cells—HRAS—head and neck cancer	0.000647	0.00198	CbGpPWpGaD
Orlistat—PLA2G4A—Opioid Signalling—MAPK1—head and neck cancer	0.000642	0.00197	CbGpPWpGaD
Orlistat—Dizziness—Docetaxel—head and neck cancer	0.000637	0.00184	CcSEcCtD
Orlistat—PLA2G4A—Endothelins—HRAS—head and neck cancer	0.00063	0.00193	CbGpPWpGaD
Orlistat—PNLIP—Metabolism of lipids and lipoproteins—PTGS2—head and neck cancer	0.000627	0.00192	CbGpPWpGaD
Orlistat—FASN—Metabolism—DPYD—head and neck cancer	0.000622	0.00191	CbGpPWpGaD
Orlistat—DAGLA—Hemostasis—MAPK3—head and neck cancer	0.000619	0.0019	CbGpPWpGaD
Orlistat—DAGLB—Hemostasis—MAPK3—head and neck cancer	0.000619	0.0019	CbGpPWpGaD
Orlistat—Vomiting—Docetaxel—head and neck cancer	0.000612	0.00177	CcSEcCtD
Orlistat—Rash—Docetaxel—head and neck cancer	0.000607	0.00176	CcSEcCtD
Orlistat—Dermatitis—Docetaxel—head and neck cancer	0.000606	0.00175	CcSEcCtD
Orlistat—Headache—Docetaxel—head and neck cancer	0.000603	0.00174	CcSEcCtD
Orlistat—FASN—Metabolism—YAP1—head and neck cancer	0.00059	0.00181	CbGpPWpGaD
Orlistat—DAGLA—Hemostasis—MAPK1—head and neck cancer	0.000589	0.00181	CbGpPWpGaD
Orlistat—DAGLB—Hemostasis—MAPK1—head and neck cancer	0.000589	0.00181	CbGpPWpGaD
Orlistat—Nausea—Docetaxel—head and neck cancer	0.000572	0.00165	CcSEcCtD
Orlistat—PLA2G4A—Fc-epsilon receptor I signaling in mast cells—AKT1—head and neck cancer	0.000571	0.00175	CbGpPWpGaD
Orlistat—PLA2G4A—Metabolism of lipids and lipoproteins—YAP1—head and neck cancer	0.000569	0.00175	CbGpPWpGaD
Orlistat—CYP3A4—Tryptophan metabolism—CYP1A1—head and neck cancer	0.000561	0.00172	CbGpPWpGaD
Orlistat—PLA2G4A—Integrated Pancreatic Cancer Pathway—CASP8—head and neck cancer	0.000559	0.00172	CbGpPWpGaD
Orlistat—PLA2G4A—PDGFR-beta signaling pathway—PTEN—head and neck cancer	0.000558	0.00171	CbGpPWpGaD
Orlistat—PLA2G4A—Endothelins—AKT1—head and neck cancer	0.000556	0.00171	CbGpPWpGaD
Orlistat—PNLIP—Metabolism of lipids and lipoproteins—PTEN—head and neck cancer	0.000547	0.00168	CbGpPWpGaD
Orlistat—PLA2G4A—AGE/RAGE pathway—AKT1—head and neck cancer	0.000536	0.00165	CbGpPWpGaD
Orlistat—PLA2G4A—Phospholipid metabolism—PTEN—head and neck cancer	0.000516	0.00158	CbGpPWpGaD
Orlistat—DAGLA—Hemostasis—PIK3CA—head and neck cancer	0.000511	0.00157	CbGpPWpGaD
Orlistat—DAGLB—Hemostasis—PIK3CA—head and neck cancer	0.000511	0.00157	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling by GPCR—KISS1—head and neck cancer	0.000507	0.00156	CbGpPWpGaD
Orlistat—PNLIP—Metabolism—TYMS—head and neck cancer	0.000501	0.00154	CbGpPWpGaD
Orlistat—PLA2G4A—PDGFR-beta signaling pathway—STAT3—head and neck cancer	0.000499	0.00153	CbGpPWpGaD
Orlistat—PNLIP—Metabolism—GSTM1—head and neck cancer	0.000495	0.00152	CbGpPWpGaD
Orlistat—DAGLA—Hemostasis—TP53—head and neck cancer	0.000495	0.00152	CbGpPWpGaD
Orlistat—DAGLB—Hemostasis—TP53—head and neck cancer	0.000495	0.00152	CbGpPWpGaD
Orlistat—DAGLB—GPCR downstream signaling—IL2—head and neck cancer	0.000487	0.00149	CbGpPWpGaD
Orlistat—DAGLA—GPCR downstream signaling—IL2—head and neck cancer	0.000487	0.00149	CbGpPWpGaD
Orlistat—PLA2G4A—Integrated Pancreatic Cancer Pathway—BCL2—head and neck cancer	0.00048	0.00147	CbGpPWpGaD
Orlistat—PLA2G4A—PDGFR-beta signaling pathway—MAPK3—head and neck cancer	0.000477	0.00146	CbGpPWpGaD
Orlistat—PNLIP—Metabolism—GPX1—head and neck cancer	0.000474	0.00146	CbGpPWpGaD
Orlistat—DAGLA—Hemostasis—HRAS—head and neck cancer	0.000473	0.00145	CbGpPWpGaD
Orlistat—DAGLB—Hemostasis—HRAS—head and neck cancer	0.000473	0.00145	CbGpPWpGaD
Orlistat—PNLIP—Metabolism—CYP1A1—head and neck cancer	0.00047	0.00144	CbGpPWpGaD
Orlistat—PLA2G4A—Integrated Pancreatic Cancer Pathway—PTGS2—head and neck cancer	0.000456	0.0014	CbGpPWpGaD
Orlistat—PLA2G4A—PDGFR-beta signaling pathway—MAPK1—head and neck cancer	0.000454	0.00139	CbGpPWpGaD
Orlistat—CYP3A4—Cytochrome P450 - arranged by substrate type—CYP1A1—head and neck cancer	0.000453	0.00139	CbGpPWpGaD
Orlistat—PNLIP—Disease—NOTCH1—head and neck cancer	0.000449	0.00138	CbGpPWpGaD
Orlistat—CYP3A4—Oxidation by Cytochrome P450—CYP1A1—head and neck cancer	0.000447	0.00137	CbGpPWpGaD
Orlistat—FASN—Metabolism of lipids and lipoproteins—PTGS2—head and neck cancer	0.000444	0.00136	CbGpPWpGaD
Orlistat—DAGLB—Signaling by GPCR—IL2—head and neck cancer	0.000442	0.00136	CbGpPWpGaD
Orlistat—DAGLA—Signaling by GPCR—IL2—head and neck cancer	0.000442	0.00136	CbGpPWpGaD
Orlistat—DAGLB—Hemostasis—AKT1—head and neck cancer	0.000418	0.00128	CbGpPWpGaD
Orlistat—DAGLA—Hemostasis—AKT1—head and neck cancer	0.000418	0.00128	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling by GPCR—GRP—head and neck cancer	0.000417	0.00128	CbGpPWpGaD
Orlistat—CYP3A4—Biological oxidations—NAT2—head and neck cancer	0.000417	0.00128	CbGpPWpGaD
Orlistat—PLA2G4A—Integrated Pancreatic Cancer Pathway—CCND1—head and neck cancer	0.000412	0.00126	CbGpPWpGaD
Orlistat—CYP3A4—Metapathway biotransformation—NAT2—head and neck cancer	0.000411	0.00126	CbGpPWpGaD
Orlistat—PLA2G4A—Integrated Pancreatic Cancer Pathway—PTEN—head and neck cancer	0.000398	0.00122	CbGpPWpGaD
Orlistat—PLA2G4A—PDGFR-beta signaling pathway—PIK3CA—head and neck cancer	0.000394	0.00121	CbGpPWpGaD
Orlistat—FASN—Metabolism of lipids and lipoproteins—PTEN—head and neck cancer	0.000387	0.00119	CbGpPWpGaD
Orlistat—PNLIP—Metabolism of lipids and lipoproteins—PIK3CA—head and neck cancer	0.000386	0.00118	CbGpPWpGaD
Orlistat—DAGLB—Signaling Pathways—NOTCH1—head and neck cancer	0.00038	0.00116	CbGpPWpGaD
Orlistat—DAGLA—Signaling Pathways—NOTCH1—head and neck cancer	0.00038	0.00116	CbGpPWpGaD
Orlistat—PLA2G4A—Platelet activation, signaling and aggregation—IL2—head and neck cancer	0.000376	0.00115	CbGpPWpGaD
Orlistat—CYP3A4—Phase 1 - Functionalization of compounds—CYP1A1—head and neck cancer	0.000368	0.00113	CbGpPWpGaD
Orlistat—PLA2G4A—PDGFR-beta signaling pathway—HRAS—head and neck cancer	0.000364	0.00112	CbGpPWpGaD
Orlistat—PLA2G4A—Phospholipid metabolism—PIK3CA—head and neck cancer	0.000364	0.00112	CbGpPWpGaD
Orlistat—PLA2G4A—Integrated Pancreatic Cancer Pathway—VEGFA—head and neck cancer	0.000359	0.0011	CbGpPWpGaD
Orlistat—DAGLB—Signaling by GPCR—MAPK3—head and neck cancer	0.000355	0.00109	CbGpPWpGaD
Orlistat—DAGLA—Signaling by GPCR—MAPK3—head and neck cancer	0.000355	0.00109	CbGpPWpGaD
Orlistat—FASN—Metabolism—TYMS—head and neck cancer	0.000355	0.00109	CbGpPWpGaD
Orlistat—FASN—Metabolism—GSTM1—head and neck cancer	0.00035	0.00108	CbGpPWpGaD
Orlistat—PLA2G4A—Integrated Pancreatic Cancer Pathway—MAPK3—head and neck cancer	0.00034	0.00104	CbGpPWpGaD
Orlistat—DAGLA—Signaling by GPCR—MAPK1—head and neck cancer	0.000338	0.00104	CbGpPWpGaD
Orlistat—DAGLB—Signaling by GPCR—MAPK1—head and neck cancer	0.000338	0.00104	CbGpPWpGaD
Orlistat—DAGLA—Signaling by GPCR—EGFR—head and neck cancer	0.000338	0.00104	CbGpPWpGaD
Orlistat—DAGLB—Signaling by GPCR—EGFR—head and neck cancer	0.000338	0.00104	CbGpPWpGaD
Orlistat—FASN—Metabolism—GPX1—head and neck cancer	0.000336	0.00103	CbGpPWpGaD
Orlistat—PNLIP—Disease—PTGS2—head and neck cancer	0.000333	0.00102	CbGpPWpGaD
Orlistat—FASN—Metabolism—CYP1A1—head and neck cancer	0.000332	0.00102	CbGpPWpGaD
Orlistat—PLA2G4A—Metabolism of lipids and lipoproteins—GPX1—head and neck cancer	0.000323	0.000992	CbGpPWpGaD
Orlistat—PLA2G4A—Integrated Pancreatic Cancer Pathway—MAPK1—head and neck cancer	0.000323	0.000992	CbGpPWpGaD
Orlistat—DAGLB—GPCR downstream signaling—PIK3CA—head and neck cancer	0.000323	0.000992	CbGpPWpGaD
Orlistat—DAGLA—GPCR downstream signaling—PIK3CA—head and neck cancer	0.000323	0.000992	CbGpPWpGaD
Orlistat—PLA2G4A—Integrated Pancreatic Cancer Pathway—EGFR—head and neck cancer	0.000323	0.000992	CbGpPWpGaD
Orlistat—PLA2G4A—Metabolism of lipids and lipoproteins—CYP1A1—head and neck cancer	0.00032	0.000982	CbGpPWpGaD
Orlistat—PLA2G4A—Platelet activation, signaling and aggregation—VEGFA—head and neck cancer	0.00032	0.000981	CbGpPWpGaD
Orlistat—FASN—Disease—NOTCH1—head and neck cancer	0.000318	0.000975	CbGpPWpGaD
Orlistat—PNLIP—Signaling Pathways—NOTCH1—head and neck cancer	0.000314	0.000965	CbGpPWpGaD
Orlistat—PLA2G4A—Metabolism—NAT2—head and neck cancer	0.000304	0.000934	CbGpPWpGaD
Orlistat—PLA2G4A—Platelet activation, signaling and aggregation—MAPK3—head and neck cancer	0.000302	0.000928	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—KISS1—head and neck cancer	0.000299	0.000919	CbGpPWpGaD
Orlistat—DAGLB—Signaling by GPCR—PIK3CA—head and neck cancer	0.000293	0.000901	CbGpPWpGaD
Orlistat—DAGLA—Signaling by GPCR—PIK3CA—head and neck cancer	0.000293	0.000901	CbGpPWpGaD
Orlistat—PNLIP—Disease—PTEN—head and neck cancer	0.000291	0.000892	CbGpPWpGaD
Orlistat—PLA2G4A—Platelet activation, signaling and aggregation—MAPK1—head and neck cancer	0.000288	0.000883	CbGpPWpGaD
Orlistat—PLA2G4A—Integrated Pancreatic Cancer Pathway—PIK3CA—head and neck cancer	0.00028	0.000861	CbGpPWpGaD
Orlistat—PNLIP—Metabolism—PTGS2—head and neck cancer	0.000279	0.000857	CbGpPWpGaD
Orlistat—FASN—Metabolism of lipids and lipoproteins—PIK3CA—head and neck cancer	0.000273	0.000838	CbGpPWpGaD
Orlistat—DAGLB—Signaling by GPCR—HRAS—head and neck cancer	0.000272	0.000833	CbGpPWpGaD
Orlistat—DAGLA—Signaling by GPCR—HRAS—head and neck cancer	0.000272	0.000833	CbGpPWpGaD
Orlistat—PLA2G4A—Integrated Pancreatic Cancer Pathway—TP53—head and neck cancer	0.000271	0.000833	CbGpPWpGaD
Orlistat—PLA2G4A—Metabolism—DPYD—head and neck cancer	0.000267	0.000819	CbGpPWpGaD
Orlistat—DAGLB—GPCR downstream signaling—AKT1—head and neck cancer	0.000264	0.00081	CbGpPWpGaD
Orlistat—DAGLA—GPCR downstream signaling—AKT1—head and neck cancer	0.000264	0.00081	CbGpPWpGaD
Orlistat—DAGLA—Signaling Pathways—IL2—head and neck cancer	0.000261	0.000801	CbGpPWpGaD
Orlistat—DAGLB—Signaling Pathways—IL2—head and neck cancer	0.000261	0.000801	CbGpPWpGaD
Orlistat—PNLIP—Disease—STAT3—head and neck cancer	0.00026	0.000798	CbGpPWpGaD
Orlistat—DAGLB—Signaling Pathways—CCND1—head and neck cancer	0.000255	0.000781	CbGpPWpGaD
Orlistat—DAGLA—Signaling Pathways—CCND1—head and neck cancer	0.000255	0.000781	CbGpPWpGaD
Orlistat—PLA2G4A—Metabolism—YAP1—head and neck cancer	0.000253	0.000777	CbGpPWpGaD
Orlistat—PLA2G4A—Platelet activation, signaling and aggregation—PIK3CA—head and neck cancer	0.00025	0.000766	CbGpPWpGaD
Orlistat—PNLIP—Disease—MAPK3—head and neck cancer	0.000248	0.000762	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—GRP—head and neck cancer	0.000247	0.000757	CbGpPWpGaD
Orlistat—DAGLB—Signaling Pathways—PTEN—head and neck cancer	0.000246	0.000754	CbGpPWpGaD
Orlistat—DAGLA—Signaling Pathways—PTEN—head and neck cancer	0.000246	0.000754	CbGpPWpGaD
Orlistat—PNLIP—Metabolism—PTEN—head and neck cancer	0.000244	0.000747	CbGpPWpGaD
Orlistat—DAGLB—Signaling by GPCR—AKT1—head and neck cancer	0.00024	0.000736	CbGpPWpGaD
Orlistat—DAGLA—Signaling by GPCR—AKT1—head and neck cancer	0.00024	0.000736	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—STAT6—head and neck cancer	0.000239	0.000735	CbGpPWpGaD
Orlistat—PNLIP—Disease—MAPK1—head and neck cancer	0.000236	0.000725	CbGpPWpGaD
Orlistat—PNLIP—Disease—EGFR—head and neck cancer	0.000236	0.000725	CbGpPWpGaD
Orlistat—FASN—Disease—PTGS2—head and neck cancer	0.000236	0.000724	CbGpPWpGaD
Orlistat—PLA2G4A—Integrated Pancreatic Cancer Pathway—AKT1—head and neck cancer	0.000229	0.000703	CbGpPWpGaD
Orlistat—DAGLB—Signaling Pathways—VEGFA—head and neck cancer	0.000222	0.000681	CbGpPWpGaD
Orlistat—DAGLA—Signaling Pathways—VEGFA—head and neck cancer	0.000222	0.000681	CbGpPWpGaD
Orlistat—DAGLA—Signaling Pathways—STAT3—head and neck cancer	0.00022	0.000674	CbGpPWpGaD
Orlistat—DAGLB—Signaling Pathways—STAT3—head and neck cancer	0.00022	0.000674	CbGpPWpGaD
Orlistat—PNLIP—Signaling Pathways—IL2—head and neck cancer	0.000216	0.000664	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—YAP1—head and neck cancer	0.000212	0.00065	CbGpPWpGaD
Orlistat—PNLIP—Signaling Pathways—CCND1—head and neck cancer	0.000211	0.000647	CbGpPWpGaD
Orlistat—DAGLB—Signaling Pathways—MAPK3—head and neck cancer	0.00021	0.000644	CbGpPWpGaD
Orlistat—DAGLA—Signaling Pathways—MAPK3—head and neck cancer	0.00021	0.000644	CbGpPWpGaD
Orlistat—CYP3A4—Biological oxidations—GSTM1—head and neck cancer	0.000206	0.000632	CbGpPWpGaD
Orlistat—FASN—Disease—PTEN—head and neck cancer	0.000206	0.000631	CbGpPWpGaD
Orlistat—PNLIP—Disease—PIK3CA—head and neck cancer	0.000205	0.000629	CbGpPWpGaD
Orlistat—PLA2G4A—Platelet activation, signaling and aggregation—AKT1—head and neck cancer	0.000204	0.000626	CbGpPWpGaD
Orlistat—PNLIP—Signaling Pathways—PTEN—head and neck cancer	0.000204	0.000625	CbGpPWpGaD
Orlistat—CYP3A4—Metapathway biotransformation—GSTM1—head and neck cancer	0.000203	0.000623	CbGpPWpGaD
Orlistat—DAGLA—Signaling Pathways—MAPK1—head and neck cancer	0.0002	0.000613	CbGpPWpGaD
Orlistat—DAGLB—Signaling Pathways—MAPK1—head and neck cancer	0.0002	0.000613	CbGpPWpGaD
Orlistat—DAGLB—Signaling Pathways—EGFR—head and neck cancer	0.0002	0.000613	CbGpPWpGaD
Orlistat—DAGLA—Signaling Pathways—EGFR—head and neck cancer	0.0002	0.000613	CbGpPWpGaD
Orlistat—FASN—Metabolism—PTGS2—head and neck cancer	0.000198	0.000606	CbGpPWpGaD
Orlistat—CYP3A4—Biological oxidations—CYP1A1—head and neck cancer	0.000195	0.000599	CbGpPWpGaD
Orlistat—PLA2G4A—Hemostasis—IL2—head and neck cancer	0.000194	0.000595	CbGpPWpGaD
Orlistat—CYP3A4—Metapathway biotransformation—CYP1A1—head and neck cancer	0.000193	0.000591	CbGpPWpGaD
Orlistat—PLA2G4A—Metabolism of lipids and lipoproteins—PTGS2—head and neck cancer	0.00019	0.000584	CbGpPWpGaD
Orlistat—PNLIP—Disease—HRAS—head and neck cancer	0.00019	0.000582	CbGpPWpGaD
Orlistat—FASN—Disease—STAT3—head and neck cancer	0.000184	0.000565	CbGpPWpGaD
Orlistat—PNLIP—Signaling Pathways—VEGFA—head and neck cancer	0.000184	0.000564	CbGpPWpGaD
Orlistat—PNLIP—Signaling Pathways—STAT3—head and neck cancer	0.000182	0.000559	CbGpPWpGaD
Orlistat—FASN—Disease—MAPK3—head and neck cancer	0.000176	0.000539	CbGpPWpGaD
Orlistat—PNLIP—Signaling Pathways—MAPK3—head and neck cancer	0.000174	0.000534	CbGpPWpGaD
Orlistat—DAGLB—Signaling Pathways—PIK3CA—head and neck cancer	0.000173	0.000532	CbGpPWpGaD
Orlistat—DAGLA—Signaling Pathways—PIK3CA—head and neck cancer	0.000173	0.000532	CbGpPWpGaD
Orlistat—FASN—Metabolism—PTEN—head and neck cancer	0.000172	0.000529	CbGpPWpGaD
Orlistat—PNLIP—Metabolism—PIK3CA—head and neck cancer	0.000172	0.000527	CbGpPWpGaD
Orlistat—CYP3A4—Metabolism—UROD—head and neck cancer	0.000172	0.000527	CbGpPWpGaD
Orlistat—DAGLB—Signaling Pathways—TP53—head and neck cancer	0.000168	0.000515	CbGpPWpGaD
Orlistat—DAGLA—Signaling Pathways—TP53—head and neck cancer	0.000168	0.000515	CbGpPWpGaD
Orlistat—PNLIP—Disease—AKT1—head and neck cancer	0.000168	0.000514	CbGpPWpGaD
Orlistat—FASN—Disease—MAPK1—head and neck cancer	0.000167	0.000513	CbGpPWpGaD
Orlistat—FASN—Disease—EGFR—head and neck cancer	0.000167	0.000513	CbGpPWpGaD
Orlistat—PLA2G4A—Metabolism of lipids and lipoproteins—PTEN—head and neck cancer	0.000166	0.000509	CbGpPWpGaD
Orlistat—PNLIP—Signaling Pathways—MAPK1—head and neck cancer	0.000166	0.000508	CbGpPWpGaD
Orlistat—PNLIP—Signaling Pathways—EGFR—head and neck cancer	0.000166	0.000508	CbGpPWpGaD
Orlistat—PLA2G4A—Hemostasis—VEGFA—head and neck cancer	0.000165	0.000505	CbGpPWpGaD
Orlistat—DAGLB—Signaling Pathways—HRAS—head and neck cancer	0.00016	0.000492	CbGpPWpGaD
Orlistat—DAGLA—Signaling Pathways—HRAS—head and neck cancer	0.00016	0.000492	CbGpPWpGaD
Orlistat—PLA2G4A—Hemostasis—MAPK3—head and neck cancer	0.000156	0.000478	CbGpPWpGaD
Orlistat—PLA2G4A—Metabolism—TYMS—head and neck cancer	0.000152	0.000467	CbGpPWpGaD
Orlistat—PLA2G4A—Metabolism—GSTM1—head and neck cancer	0.00015	0.000461	CbGpPWpGaD
Orlistat—PLA2G4A—Hemostasis—MAPK1—head and neck cancer	0.000148	0.000455	CbGpPWpGaD
Orlistat—FASN—Disease—PIK3CA—head and neck cancer	0.000145	0.000445	CbGpPWpGaD
Orlistat—PLA2G4A—Metabolism—GPX1—head and neck cancer	0.000144	0.000442	CbGpPWpGaD
Orlistat—PNLIP—Signaling Pathways—PIK3CA—head and neck cancer	0.000144	0.000441	CbGpPWpGaD
Orlistat—PLA2G4A—Metabolism—CYP1A1—head and neck cancer	0.000143	0.000437	CbGpPWpGaD
Orlistat—DAGLB—Signaling Pathways—AKT1—head and neck cancer	0.000142	0.000435	CbGpPWpGaD
Orlistat—DAGLA—Signaling Pathways—AKT1—head and neck cancer	0.000142	0.000435	CbGpPWpGaD
Orlistat—PNLIP—Metabolism—AKT1—head and neck cancer	0.00014	0.000431	CbGpPWpGaD
Orlistat—PNLIP—Signaling Pathways—TP53—head and neck cancer	0.000139	0.000426	CbGpPWpGaD
Orlistat—FASN—Disease—HRAS—head and neck cancer	0.000134	0.000412	CbGpPWpGaD
Orlistat—PNLIP—Signaling Pathways—HRAS—head and neck cancer	0.000133	0.000408	CbGpPWpGaD
Orlistat—PLA2G4A—Hemostasis—PIK3CA—head and neck cancer	0.000129	0.000395	CbGpPWpGaD
Orlistat—PLA2G4A—Hemostasis—TP53—head and neck cancer	0.000124	0.000382	CbGpPWpGaD
Orlistat—FASN—Metabolism—PIK3CA—head and neck cancer	0.000122	0.000373	CbGpPWpGaD
Orlistat—PLA2G4A—Hemostasis—HRAS—head and neck cancer	0.000119	0.000365	CbGpPWpGaD
Orlistat—FASN—Disease—AKT1—head and neck cancer	0.000119	0.000364	CbGpPWpGaD
Orlistat—PNLIP—Signaling Pathways—AKT1—head and neck cancer	0.000117	0.00036	CbGpPWpGaD
Orlistat—PLA2G4A—Metabolism of lipids and lipoproteins—PIK3CA—head and neck cancer	0.000117	0.000359	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling by GPCR—IL2—head and neck cancer	0.000111	0.000341	CbGpPWpGaD
Orlistat—PLA2G4A—Hemostasis—AKT1—head and neck cancer	0.000105	0.000323	CbGpPWpGaD
Orlistat—FASN—Metabolism—AKT1—head and neck cancer	9.93e-05	0.000305	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—NOTCH1—head and neck cancer	9.55e-05	0.000293	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling by GPCR—MAPK3—head and neck cancer	8.94e-05	0.000274	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling by GPCR—MAPK1—head and neck cancer	8.51e-05	0.000261	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling by GPCR—EGFR—head and neck cancer	8.51e-05	0.000261	CbGpPWpGaD
Orlistat—PLA2G4A—Metabolism—PTGS2—head and neck cancer	8.48e-05	0.00026	CbGpPWpGaD
Orlistat—PLA2G4A—Metabolism—PTEN—head and neck cancer	7.39e-05	0.000227	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling by GPCR—PIK3CA—head and neck cancer	7.38e-05	0.000227	CbGpPWpGaD
Orlistat—CYP3A4—Metabolism—NAT2—head and neck cancer	7.13e-05	0.000219	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling by GPCR—HRAS—head and neck cancer	6.83e-05	0.00021	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—IL2—head and neck cancer	6.57e-05	0.000202	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—CCND1—head and neck cancer	6.41e-05	0.000197	CbGpPWpGaD
Orlistat—CYP3A4—Metabolism—DPYD—head and neck cancer	6.25e-05	0.000192	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—PTEN—head and neck cancer	6.18e-05	0.00019	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling by GPCR—AKT1—head and neck cancer	6.03e-05	0.000185	CbGpPWpGaD
Orlistat—CYP3A4—Metabolism—YAP1—head and neck cancer	5.93e-05	0.000182	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—VEGFA—head and neck cancer	5.58e-05	0.000171	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—STAT3—head and neck cancer	5.53e-05	0.00017	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—MAPK3—head and neck cancer	5.28e-05	0.000162	CbGpPWpGaD
Orlistat—PLA2G4A—Metabolism—PIK3CA—head and neck cancer	5.22e-05	0.00016	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—MAPK1—head and neck cancer	5.03e-05	0.000154	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—EGFR—head and neck cancer	5.03e-05	0.000154	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—PIK3CA—head and neck cancer	4.36e-05	0.000134	CbGpPWpGaD
Orlistat—PLA2G4A—Metabolism—AKT1—head and neck cancer	4.26e-05	0.000131	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—TP53—head and neck cancer	4.22e-05	0.000129	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—HRAS—head and neck cancer	4.04e-05	0.000124	CbGpPWpGaD
Orlistat—CYP3A4—Metabolism—TYMS—head and neck cancer	3.56e-05	0.000109	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—AKT1—head and neck cancer	3.56e-05	0.000109	CbGpPWpGaD
Orlistat—CYP3A4—Metabolism—GSTM1—head and neck cancer	3.52e-05	0.000108	CbGpPWpGaD
Orlistat—CYP3A4—Metabolism—GPX1—head and neck cancer	3.37e-05	0.000103	CbGpPWpGaD
Orlistat—CYP3A4—Metabolism—CYP1A1—head and neck cancer	3.34e-05	0.000102	CbGpPWpGaD
Orlistat—CYP3A4—Metabolism—PTGS2—head and neck cancer	1.99e-05	6.09e-05	CbGpPWpGaD
Orlistat—CYP3A4—Metabolism—PTEN—head and neck cancer	1.73e-05	5.31e-05	CbGpPWpGaD
Orlistat—CYP3A4—Metabolism—PIK3CA—head and neck cancer	1.22e-05	3.75e-05	CbGpPWpGaD
Orlistat—CYP3A4—Metabolism—AKT1—head and neck cancer	9.98e-06	3.06e-05	CbGpPWpGaD
